Posted by Michael Wonder on 05 May 2021
Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
5 May 2021 - This approval marks Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the European Union.
Roche today announced that the European Commission has approved Tecentriq (atezolizumab) as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumours have high PD-L1 expression, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumour aberrations.
